-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
As the core resource of the medical ecological supply side, the medical device industry is receiving strong support from national policies under technological changes
.
In recent years, the development of China's medical device industry has clearly entered the fast lane, and the performance of many machinery companies is also developing continuously
.
Recently, Mindray Medical released the "2021 Third Quarter Report"
.
The report shows that in the first three quarters of 2021, the company achieved operating income of 19.
391 billion yuan, an increase of 20.
72% over the same period last year
.
The net profit attributable to shareholders of listed companies was 6.
662 billion yuan, an increase of 24.
23% over the same period last year
.
Regarding the third-quarter performance, Mindray Medical stated in the record sheet that the performance growth was due to the development of new domestic medical infrastructure and the recovery of conventional businesses
.
The domestic life information and support production line has achieved a rapid growth of more than 50%
.
Both domestic in vitro diagnostic and medical imaging businesses that were damaged by the epidemic last year achieved a rebound growth of more than 35%
.
In addition to Mindray Medical, on October 15th, A-share listed company Ingram Medical also issued a three-quarter report performance forecast.
The company expects that its performance will rise sharply from January to September 2021, and the net profit attributable to shareholders of the listed company will be 6.
779 billion to 6.
979 billion.
The net profit increased by 55.
03% year-on-year to 59.
60%.
The company's industry is medical equipment
.
On October 14, Tongce Medical released a third-quarter report showing that in the first three quarters, the company achieved operating income of 2.
136 billion yuan, a year-on-year increase of 44.
16%; realized a net profit of 620 million yuan, an increase of 55.
09%; The profit was 608 million yuan, an increase of 56.
69% year-on-year; the three indicators increased by 50.
32%, 55.
12%, and 54.
71% respectively compared to 2019
.
On the whole, the general increase in the performance of medical companies in the first three quarters is mainly due to the huge challenges that the epidemic has brought to the domestic medical and disease control system, and the country's emphasis on medical investment has been greatly increased; and the routine of domestic hospitals Diagnosis and treatment activities and the company’s various businesses have gradually returned to normal, and the demand for medical devices has also continued to expand..
The industry predicts that with the intensification of aging, people’s health awareness and consumption levels will continue to increase, per capita healthcare consumption expenditure will continue to rise, coupled with the advancement of new infrastructure, as well as hierarchical diagnosis and treatment, mass procurement, DRGs, medical device registrants With the implementation of the system and other policies and the acceleration of domestic substitution of imports, the development of the domestic medical device industry will continue to develop at a relatively rapid rate, and the market scale will continue to expand
.
Data show that the size of China's medical device market in 2020 is about 734.
1 billion yuan, an increase of 18.
3% year-on-year
.
Following this trend, in the next 5 years, the average annual compound growth rate of the medical device market is expected to be about 14%, and it will exceed one trillion by 2023
.
It should be noted that despite the rapid development of Chinese medical companies in recent years, due to their relatively short development time and weak foundation, there is still a certain gap compared with countries with high levels of medical device development such as the United States, Europe, and Japan.
In the field of technology-intensive high-end medical equipment, it is still mainly occupied by imported medical equipment; in addition, some medical equipment in China still have problems such as product performance homogeneity
.
In this regard, analysts believe that with the accelerated development of the medical device industry, the domestic medical device industry urgently needs to master more independent intellectual property rights and technological innovation for high-end medical devices
.
In addition
.
Domestic enterprises also need to focus deeply on the frontiers, seek unseen technologies from the source of life sciences, and allow technological innovation achievements to continue to promote the healthy development of the industry
.
.
In recent years, the development of China's medical device industry has clearly entered the fast lane, and the performance of many machinery companies is also developing continuously
.
Recently, Mindray Medical released the "2021 Third Quarter Report"
.
The report shows that in the first three quarters of 2021, the company achieved operating income of 19.
391 billion yuan, an increase of 20.
72% over the same period last year
.
The net profit attributable to shareholders of listed companies was 6.
662 billion yuan, an increase of 24.
23% over the same period last year
.
Regarding the third-quarter performance, Mindray Medical stated in the record sheet that the performance growth was due to the development of new domestic medical infrastructure and the recovery of conventional businesses
.
The domestic life information and support production line has achieved a rapid growth of more than 50%
.
Both domestic in vitro diagnostic and medical imaging businesses that were damaged by the epidemic last year achieved a rebound growth of more than 35%
.
In addition to Mindray Medical, on October 15th, A-share listed company Ingram Medical also issued a three-quarter report performance forecast.
The company expects that its performance will rise sharply from January to September 2021, and the net profit attributable to shareholders of the listed company will be 6.
779 billion to 6.
979 billion.
The net profit increased by 55.
03% year-on-year to 59.
60%.
The company's industry is medical equipment
.
On October 14, Tongce Medical released a third-quarter report showing that in the first three quarters, the company achieved operating income of 2.
136 billion yuan, a year-on-year increase of 44.
16%; realized a net profit of 620 million yuan, an increase of 55.
09%; The profit was 608 million yuan, an increase of 56.
69% year-on-year; the three indicators increased by 50.
32%, 55.
12%, and 54.
71% respectively compared to 2019
.
On the whole, the general increase in the performance of medical companies in the first three quarters is mainly due to the huge challenges that the epidemic has brought to the domestic medical and disease control system, and the country's emphasis on medical investment has been greatly increased; and the routine of domestic hospitals Diagnosis and treatment activities and the company’s various businesses have gradually returned to normal, and the demand for medical devices has also continued to expand..
The industry predicts that with the intensification of aging, people’s health awareness and consumption levels will continue to increase, per capita healthcare consumption expenditure will continue to rise, coupled with the advancement of new infrastructure, as well as hierarchical diagnosis and treatment, mass procurement, DRGs, medical device registrants With the implementation of the system and other policies and the acceleration of domestic substitution of imports, the development of the domestic medical device industry will continue to develop at a relatively rapid rate, and the market scale will continue to expand
.
Data show that the size of China's medical device market in 2020 is about 734.
1 billion yuan, an increase of 18.
3% year-on-year
.
Following this trend, in the next 5 years, the average annual compound growth rate of the medical device market is expected to be about 14%, and it will exceed one trillion by 2023
.
It should be noted that despite the rapid development of Chinese medical companies in recent years, due to their relatively short development time and weak foundation, there is still a certain gap compared with countries with high levels of medical device development such as the United States, Europe, and Japan.
In the field of technology-intensive high-end medical equipment, it is still mainly occupied by imported medical equipment; in addition, some medical equipment in China still have problems such as product performance homogeneity
.
In this regard, analysts believe that with the accelerated development of the medical device industry, the domestic medical device industry urgently needs to master more independent intellectual property rights and technological innovation for high-end medical devices
.
In addition
.
Domestic enterprises also need to focus deeply on the frontiers, seek unseen technologies from the source of life sciences, and allow technological innovation achievements to continue to promote the healthy development of the industry
.
